Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia.

about

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q41925673

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Comparison of effectiveness an ...... t of chronic myeloid leukemia.

@en

type

Item

label

Comparison of effectiveness an ...... t of chronic myeloid leukemia.

@en

prefLabel

Comparison of effectiveness an ...... t of chronic myeloid leukemia.

@en

P1476

Comparison of effectiveness an ...... t of chronic myeloid leukemia.

@en

P2093

Alireza Hajiannejad

http://www.w3.org/2001/XMLSchema#string

Farah Esmaili

http://www.w3.org/2001/XMLSchema#string

Kamran Moshfeghi

http://www.w3.org/2001/XMLSchema#string

Neda Nazemzadeh

http://www.w3.org/2001/XMLSchema#string

Valiollah Mehrzad

http://www.w3.org/2001/XMLSchema#string

P2860

Practical management of patients with chronic myeloid leukemia.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Practical management of patients with chronic myeloid leukemia receiving imatinib.

The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Current status of imatinib as frontline therapy for chronic myeloid leukemia.

New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2277-9175.108000

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23930262

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

3732876

http://www.w3.org/2001/XMLSchema#string